Don't Review Invalidation Of Apotex Patent, Fed. Circ. Told
UCB Inc. urged the full Federal Circuit on Friday not to reconsider a decision that an Apotex Inc. blood pressure drug patent is invalid due to inequitable conduct by the company's...To view the full article, register now.
Already a subscriber? Click here to view full article